These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
422 related articles for article (PubMed ID: 23897183)
1. Treatment by long haemodialysis sessions with high cut-off filters in myeloma cast nephropathy: our experience. Borrego-Hinojosa J; Pérez-del Barrio MP; Biechy-Baldan Mdel M; Merino-García E; Sánchez-Perales MC; García-Cortés MJ; Ocaña-Pérez E; Gutiérrez-Rivas P; Liébana-Cañada A Nefrologia; 2013; 33(4):515-23. PubMed ID: 23897183 [TBL] [Abstract][Full Text] [Related]
2. Haemodialysis using high cut-off dialysers for treating acute renal failure in multiple myeloma. Martín-Reyes G; Toledo-Rojas R; Torres-de Rueda Á; Sola-Moyano E; Blanca-Martos L; Fuentes-Sánchez L; Martínez-Esteban MD; Díez-de los Ríos MJ; Bailén-García A; González-Molina M; García-González I Nefrologia; 2012; 32(1):35-43. PubMed ID: 22294003 [TBL] [Abstract][Full Text] [Related]
3. Immunoglobulin free light chain levels and recovery from myeloma kidney on treatment with chemotherapy and high cut-off haemodialysis. Hutchison CA; Heyne N; Airia P; Schindler R; Zickler D; Cook M; Cockwell P; Grima D Nephrol Dial Transplant; 2012 Oct; 27(10):3823-8. PubMed ID: 22273664 [TBL] [Abstract][Full Text] [Related]
4. Thirteen treated of acute renal failure secondary to multiple myeloma with high cut off filters. Berni Wennekers A; Martín Azara MP; Dourdil Sahun V; Bergasa Liberal B; Ruiz Laiglesia JE; Vernet Perna P; Alvarez Lipe R Nefrologia; 2016; 36(4):418-26. PubMed ID: 27255910 [TBL] [Abstract][Full Text] [Related]
5. Management options for cast nephropathy in multiple myeloma. Cockwell P; Hutchison CA Curr Opin Nephrol Hypertens; 2010 Nov; 19(6):550-5. PubMed ID: 20827195 [TBL] [Abstract][Full Text] [Related]
6. Effectiveness of IHD with Adsorptive PMMA Membrane in Myeloma Cast Nephropathy: A Cohort Study. Sens F; Chaintreuil D; Jolivot A; Guebre-Egziabher F; Robinson P; Karlin L; Bridoux F; Juillard L Am J Nephrol; 2017; 46(5):355-363. PubMed ID: 29017155 [TBL] [Abstract][Full Text] [Related]
7. Evaluation of blood purification and bortezomib plus dexamethasone therapy for the treatment of acute renal failure due to myeloma cast nephropathy. Hasegawa M; Kondo F; Yamamoto K; Murakami K; Tomita M; Nabeshima K; Nakai S; Kato M; Ohashi A; Arai J; Hiki Y; Ishii J; Emi N; Sugiyama S; Yuzawa Y Ther Apher Dial; 2010 Oct; 14(5):451-6. PubMed ID: 21175542 [TBL] [Abstract][Full Text] [Related]
8. Extended high cut-off haemodialysis for myeloma cast nephropathy in Auckland, 2008-2012. Tan J; Lam-Po-Tang M; Hutchison CA; de Zoysa JR Nephrology (Carlton); 2014 Jul; 19(7):432-5. PubMed ID: 24931113 [TBL] [Abstract][Full Text] [Related]
9. Efficient removal of immunoglobulin free light chains by hemodialysis for multiple myeloma: in vitro and in vivo studies. Hutchison CA; Cockwell P; Reid S; Chandler K; Mead GP; Harrison J; Hattersley J; Evans ND; Chappell MJ; Cook M; Goehl H; Storr M; Bradwell AR J Am Soc Nephrol; 2007 Mar; 18(3):886-95. PubMed ID: 17229909 [TBL] [Abstract][Full Text] [Related]
10. Cast nephropathy with acute renal failure treated with high cut-off haemodialysis in a patient with multiple myeloma. Shum HP; Chan KC; Chow CC; Kho BC; Yan WW Hong Kong Med J; 2010 Dec; 16(6):489-92. PubMed ID: 21135429 [TBL] [Abstract][Full Text] [Related]
11. Effectiveness of Haemodiafiltration with Heat Sterilized High-Flux Polyphenylene HF Dialyzer in Reducing Free Light Chains in Patients with Myeloma Cast Nephropathy. Rousseau-Gagnon M; Agharazii M; De Serres SA; Desmeules S PLoS One; 2015; 10(10):e0140463. PubMed ID: 26466100 [TBL] [Abstract][Full Text] [Related]
12. Successful use of combined high cut-off haemodialysis and bortezomib for acute kidney injury associated with myeloma cast nephropathy. Ward F; Dunne O; Crotty TB; Fennelly D; Watson A; Holian J Ir Med J; 2012 May; 105(5):148-9. PubMed ID: 22803494 [TBL] [Abstract][Full Text] [Related]
15. Impact of free light chain hemodialysis in myeloma cast nephropathy: a case-control study. Peters NO; Laurain E; Cridlig J; Hulin C; Cao-Huu T; Frimat L Hemodial Int; 2011 Oct; 15(4):538-45. PubMed ID: 22111823 [TBL] [Abstract][Full Text] [Related]
16. High cut-off hemodialysis and bortezomib-based therapy to rescue kidneys in myeloma-dependent cast nephropathy. Sinisalo M; Silvennoinen R; Wirta O Am J Hematol; 2012 Jun; 87(6):640. PubMed ID: 22473521 [TBL] [Abstract][Full Text] [Related]
17. Aggregated serum free light chains may prevent adequate removal by high cut-off haemodialysis. Harding S; Provot F; Beuscart JB; Cook M; Bradwell AR; Stringer S; White D; Cockwell P; Hutchison CA Nephrol Dial Transplant; 2011 Apr; 26(4):1438. PubMed ID: 21406545 [TBL] [Abstract][Full Text] [Related]
18. Patients with multiple myeloma have excellent long-term outcomes after recovery from dialysis-dependent acute kidney injury. Yadav P; Hutchison CA; Basnayake K; Stringer S; Jesky M; Fifer L; Snell K; Pinney J; Drayson MT; Cook M; Cockwell P Eur J Haematol; 2016 Jun; 96(6):610-7. PubMed ID: 26248588 [TBL] [Abstract][Full Text] [Related]
19. The rationale and evidence base for the direct removal of serum-free light chains in the management of myeloma kidney. Cockwell P; Cook M Adv Chronic Kidney Dis; 2012 Sep; 19(5):324-32. PubMed ID: 22920643 [TBL] [Abstract][Full Text] [Related]
20. Effectiveness of haemodiafiltration with ultrafiltrate regeneration in the reduction of light chains in multiple myeloma with renal failure. Pendón-Ruiz de Mier MV; Alvarez-Lara MA; Ojeda-López R; Martín-Malo A; Carracedo J; Caballero-Villarraso J; Alonso C; Aljama P Nefrologia; 2013 Nov; 33(6):788-96. PubMed ID: 24241366 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]